osimertinib,gefitinib
astrazeneca
['gefitinib', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'flaura', 'osimertinib']
phase iii trial comparing egfr-tki (gefitinib or osimertinib) monotherapy and tki with inserted platinum doublet (3 cycles) in egfr(+) nsclc, jcog1404/wjog8214l (again study ) by dr. shintaro kanda. negative study with pfs/os hr 0.762/0.985. #asco23 #lcsm #flaura2 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC